Long-Term Efficacy of a Novel Ribose–Cross-linked Collagen Dermal Filler

Efficacy and Tolerability of Admixing 0.3% Lidocaine with Dermicol-P35 27G for the Treatment of Nasolabial Folds

“…It will be of interest to evaluate the long‐term efficacy and safety of and patient satisfaction with Dermicol‐P35 27G/0.3% lidocaine in a larger set of patients to confirm the results observed here. Given the established properties of Dermicol‐P35 27G as stable and nontoxic, with a low risk for immunogenicity, 6–8 the proven efficacy of treatment of NLFs, 5 and the data from the current study, Dermicol‐P35 27G/0.3% lidocaine may represent a new option for enhanced patient comfort and satisfaction.…”

“…Dermicol‐P35 27G (Evolence, Ortho Dermatologics Inc., Los Angeles, CA) is a type I porcine collagen–based dermal filler that is ribose cross‐linked using patented Glymatrix technology 5 . Dermicol‐P35 27G is durable, 6,7 does not have the toxicity associated with glutaraldehyde, and has a low potential for hypersensitivity 8 . In a randomized, multicenter study, Dermicol‐P35 27G was as effective as non‐animal‐stabilized hyaluronic acid for reducing the Modified Fitzpatrick Wrinkle Scale (MFWS) score in the treatment of nasolabial folds (NLFs) 5 .…”

Development of Poly(HEMA-Am) Polymer Hydrogel Filler for Soft Tissue Reconstruction by Facile Polymerization

“…Nonetheless, they are associated with a high incidence of side effects such as low biocompatibility [18]. Synthetic materials include acrylamide, poly(methylmethacrylate, PMMA), silicone, polycaprolactone (PCL), and poly- l -lactic acid (PLLA) [19]. However, they have the disadvantage of long periods of residual time due to tissue resistance such as a severe inflammatory reaction, granuloma formation, ulceration and migration [20].…”

A Randomized, Multicenter Study of the Safety and Efficacy of Dermicol-P35 and Non-Animal-Stabilized Hyaluronic Acid Gel for the Correction of Nasolabial Folds

“…The product is a gel derived from porcine collagen and prepared via a process that includes enzymatic digestion to remove the antigenic portions of the molecule, making it immunologically compatible with humans, without disturbing its natural helical structure. Dermicol‐P35 is cross‐linked with a naturally occurring sugar (ribose) metabolite using a unique cross‐linking technology that is believed to slow its resorption rate in vivo 5 …”